Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stake Raised by Spruce Street Capital LP

Spruce Street Capital LP lifted its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 528.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 489,849 shares of the company’s stock after acquiring an additional 411,852 shares during the quarter. Centessa Pharmaceuticals accounts for 4.7% of Spruce Street Capital LP’s portfolio, making the stock its 7th largest position. Spruce Street Capital LP owned about 0.33% of Centessa Pharmaceuticals worth $19,457,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC raised its position in Centessa Pharmaceuticals by 34.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after purchasing an additional 3,747,475 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in shares of Centessa Pharmaceuticals by 12.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,281,741 shares of the company’s stock valued at $282,156,000 after buying an additional 1,246,741 shares during the period. Farallon Capital Management LLC grew its stake in shares of Centessa Pharmaceuticals by 24.1% during the fourth quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company’s stock valued at $134,480,000 after buying an additional 1,045,750 shares during the last quarter. Siren L.L.C. grew its stake in shares of Centessa Pharmaceuticals by 24.8% during the fourth quarter. Siren L.L.C. now owns 4,027,517 shares of the company’s stock valued at $100,728,000 after buying an additional 800,000 shares during the last quarter. Finally, Commodore Capital LP raised its holdings in shares of Centessa Pharmaceuticals by 39.3% in the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after buying an additional 930,711 shares during the period. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. B. Riley Financial lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Finally, Wolfe Research lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Four analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $40.50 on Friday. The firm has a market cap of $6.27 billion, a PE ratio of -22.63 and a beta of 1.11. The firm’s 50 day simple moving average is $40.14 and its 200-day simple moving average is $33.69. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $12.74 and a one year high of $40.56. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.